Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases

DNA demethylating agents may increase the immunogenicity of malignant tumours and increase the efficacy of subsequent treatment with immune check point inhibitors. We investigated the safety of administrating the demethylating agent decitabine by hepatic arterial infusionin patients with unresectabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansen, Yanina J L, Verset, Gontran, Schats, Kelly, Van Dam, Pieter-Jan, Seremet, Teofila, Kockx, Mark, Van Laethem, Jean-Luc B, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435241/
https://www.ncbi.nlm.nih.gov/pubmed/30962963
http://dx.doi.org/10.1136/esmoopen-2018-000464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435241/
https://www.ncbi.nlm.nih.gov/pubmed/30962963
http://dx.doi.org/10.1136/esmoopen-2018-000464

Ejemplares similares